Autres langues ZyVersa Therapeutics, Inc.

Actions

ZVSA

US98987D3008

Recherche biotechnologique et médicale

Temps Différé OTC Markets 15:30:02 28/09/2026			Varia. 5j.	Varia. 1 janv.
0,1149 ^USD	+16,06%		+16,06%	-14,00%

10/07	Zyversa Therapeutics, Inc. annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 8 juillet 2026	CI
13/05	ZyVersa Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

10/07	Zyversa Therapeutics, Inc. Announces Board and Committee Changes, Effective July 8, 2026
13/05	ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
13/05	ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
31/03	ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
31/03	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	ZyVersa Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
27/02	ZyVersa Therapeutics, Inc. announced that it has received $1 million in funding
03/12	ZyVersa Therapeutics, Inc. Announces Resignation of Robert G. Finizio from Board and Committee Positions, Effective December 2, 2025
19/11	ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
19/11	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
15/10/25	ZyVersa Therapeutics, Inc. Announces Resignation of Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs
10/09/25	ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
03/09/25	Zyversa Therapeutics Highlights Lipidomic Data in Alport Syndrome and Dkd Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
03/09/25	ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
14/08/25	Zyversa Therapeutics Highlights Data Demonstrating A Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease and Its Progression
14/08/25	ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
13/08/25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
13/08/25	ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
21/07/25	ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
21/07/25	ZyVersa Therapeutics, Inc.(NasdaqCM:ZVSA) dropped from S&P TMI Index
16/07/25	ZyVersa Therapeutics, Inc.(NasdaqCM:ZVSA) dropped from NASDAQ Composite Index
08/07/25	ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
08/07/25	ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis
08/07/25	ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
26/06/25	ZyVersa Therapeutics, Inc. Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease